These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 18472213)
21. [Milk Thistle (Silybum Marianum) as a Supportive Phytotherapeutic Agent in Oncology]. Frassová Z; Rudá-Kučerová J Klin Onkol; 2017; 30(6):426-432. PubMed ID: 29271213 [TBL] [Abstract][Full Text] [Related]
22. Silybin and silymarin--new and emerging applications in medicine. Gazák R; Walterová D; Kren V Curr Med Chem; 2007; 14(3):315-38. PubMed ID: 17305535 [TBL] [Abstract][Full Text] [Related]
23. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Deep G; Oberlies NH; Kroll DJ; Agarwal R Carcinogenesis; 2007 Jul; 28(7):1533-42. PubMed ID: 17389612 [TBL] [Abstract][Full Text] [Related]
24. Silymarin as a preventive or therapeutic measure for chemotherapy and radiotherapy-induced adverse reactions: a comprehensive review of preclinical and clinical data. Ghodousi M; Karbasforooshan H; Arabi L; Elyasi S Eur J Clin Pharmacol; 2023 Jan; 79(1):15-38. PubMed ID: 36450892 [TBL] [Abstract][Full Text] [Related]
25. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. Hogan FS; Krishnegowda NK; Mikhailova M; Kahlenberg MS J Surg Res; 2007 Nov; 143(1):58-65. PubMed ID: 17950073 [TBL] [Abstract][Full Text] [Related]
26. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review. Tajmohammadi A; Razavi BM; Hosseinzadeh H Phytother Res; 2018 Oct; 32(10):1933-1949. PubMed ID: 30015401 [TBL] [Abstract][Full Text] [Related]
27. Silibinin inhibits tumor promotional triggers and tumorigenesis against chemically induced two-stage skin carcinogenesis in Swiss albino mice: possible role of oxidative stress and inflammation. Khan AQ; Khan R; Tahir M; Rehman MU; Lateef A; Ali F; Hamiza OO; Hasan SK; Sultana S Nutr Cancer; 2014; 66(2):249-58. PubMed ID: 24364787 [TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of silibinin on tumour necrosis factor-alpha and hydrogen peroxide production by human monocytes. Bannwart CF; Peraçoli JC; Nakaira-Takahagi E; Peraçoli MT Nat Prod Res; 2010 Nov; 24(18):1747-57. PubMed ID: 20981616 [TBL] [Abstract][Full Text] [Related]
29. Silibinin--a promising new treatment for cancer. Cheung CW; Gibbons N; Johnson DW; Nicol DL Anticancer Agents Med Chem; 2010 Mar; 10(3):186-95. PubMed ID: 20015009 [TBL] [Abstract][Full Text] [Related]
30. Silymarin and Its Role in Chronic Diseases. Neha ; Jaggi AS; Singh N Adv Exp Med Biol; 2016; 929():25-44. PubMed ID: 27771919 [TBL] [Abstract][Full Text] [Related]
31. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Zhao J; Agarwal R Carcinogenesis; 1999 Nov; 20(11):2101-8. PubMed ID: 10545412 [TBL] [Abstract][Full Text] [Related]
32. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Bijak M Molecules; 2017 Nov; 22(11):. PubMed ID: 29125572 [TBL] [Abstract][Full Text] [Related]
33. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review. Polachi N; Bai G; Li T; Chu Y; Wang X; Li S; Gu N; Wu J; Li W; Zhang Y; Zhou S; Sun H; Liu C Eur J Med Chem; 2016 Nov; 123():577-595. PubMed ID: 27517806 [TBL] [Abstract][Full Text] [Related]
34. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Federico A; Dallio M; Loguercio C Molecules; 2017 Jan; 22(2):. PubMed ID: 28125040 [TBL] [Abstract][Full Text] [Related]
35. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. de Oliveira DR; Tintino SR; Braga MF; Boligon AA; Athayde ML; Coutinho HD; de Menezes IR; Fachinetto R Biomed Res Int; 2015; 2015():292797. PubMed ID: 25866771 [TBL] [Abstract][Full Text] [Related]
36. Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. Gharagozloo M; Amirghofran Z J Cancer Res Clin Oncol; 2007 Aug; 133(8):525-32. PubMed ID: 17436018 [TBL] [Abstract][Full Text] [Related]
37. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Singh RP; Tyagi AK; Zhao J; Agarwal R Carcinogenesis; 2002 Mar; 23(3):499-510. PubMed ID: 11895866 [TBL] [Abstract][Full Text] [Related]
38. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases. Gharagozloo M; Javid EN; Rezaei A; Mousavizadeh K Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):251-6. PubMed ID: 23121838 [TBL] [Abstract][Full Text] [Related]